Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen a nearly 4% increase in stock price following the approval of six new specifications for its self-developed polylactic acid facial filler, known as "童颜针" (youthful needle), by the National Medical Products Administration of China, marking a significant advancement in the company's regenerative aesthetic product portfolio [1] Group 1: Company Developments - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, expanding the product range and enhancing market offerings [1] - Prior to this expansion, the product had already received approval for three specifications: 45mg, 75mg, and 150mg bottles, catering to different needs such as preventive management, combination therapy, and comprehensive rejuvenation [1] Group 2: Market Impact - The stock price of Four Seasons Pharmaceutical rose by 3.94%, reaching HKD 1.32, with a trading volume of 12.825 million HKD, indicating positive market sentiment following the announcement [1]

Major Developments - Four Seasons Pharmaceutical (00460) has received approval from the National Medical Products Administration for a new specification of its "Youthful Needle" product [1] - Jixing New Energy (03395) has obtained regulatory approval for a 9.6 MW natural gas power generation project and board approval for a new 75,000 tons/year liquefied natural gas project [1] - Tiangong International (00826) has signed an agreement for a joint laboratory focused on the research and development of high-end fusion metal materials, aiming to explore downstream applications of controllable nuclear fusion [1] - Huashang Energy (00206) has announced a strategic plan for the next five years (2026-2030), aiming to become a leading green energy and equipment service provider in China [1] - Tianyu Semiconductor (02658) has entered into a strategic cooperation agreement with Qinghe Crystal to jointly develop bonding materials and technology iterations [1] - China Ruyi (00136) plans to invest approximately $14.2 million in AIsphere to explore innovative applications of artificial intelligence technology in film, streaming, and gaming content production and operations [1] Operating Performance - Shimao Group (00813) reported a cumulative contract sales total of approximately 23.953 billion yuan for 2025 [1] - China Shenhua (01088) expects coal sales volume to reach 431 million tons in 2025, a year-on-year decrease of 6.4% [1] - New China Life Insurance (01336) reported a cumulative original insurance premium income of 195.899 billion yuan for 2025, a year-on-year increase of 15% [1] - Ronshine China (03301) anticipates a total contract sales amount of approximately 3.777 billion yuan for 2025, a year-on-year decrease of 50.96% [1] - Hu Shang Ayi (02589) has issued a profit warning, expecting a net profit for 2025 to be between 495 million and 525 million yuan, a year-on-year increase of approximately 50% to 60% [1] - TCL Electronics (01070) has issued a profit warning, expecting adjusted net profit for 2025 to be between 2.33 billion and 2.57 billion Hong Kong dollars, a year-on-year increase of approximately 45% to 60% [1]

作为国内唯一同时持有合规"少女针"、"童颜针"两大再生填充产品，且同时还有肉毒毒素，水光针和黄 金微针等重磅叁类医疗器械医美品种的企业，四环医药童颜针凭藉左旋聚乳酸(PLLA)微球核心成分， 实现"即时填充+长效再生"的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全性与临 床疗效均表现优异，多数患者注射后1年仍能维持有效效果。此次规格拓展前，产品已获批45mg╱瓶、 75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联合治疗及综合年轻化等不同需求;新增获批 的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、120mg╱瓶、130mg╱瓶六类规格，将进一步丰富 产品选择谱系。 智通财经APP讯，四环医药(00460)发布公告，集团旗下渼颜空间生物科技(吉林)有限公司自主研发的聚 乳酸面部填充剂(市场简称"童颜针")6个新增规格正式获中国国家药品监督管理局批准，这是继该产品 首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 2.优化临床操作灵活性：依託产品1分钟快速复溶的特性，多规格选择让医生可根据注射部位、治疗层 次灵活调整稀释浓度与注射剂量，减少联合用药 ...

作为国内唯一同时持有合规「少女针」、「童颜针」两大再生填充产品，且同时还有肉毒毒素，水光针 和黄金微针等重磅三类医疗器械医美品种的企业，四环医药童颜针凭藉左旋聚乳酸(PLLA)微球核心成 分，实现「即时填充+长效再生」的双重功效，其独特专利技术保障了微球形态规则、粒径均一，安全 性与临床疗效均表现优异，多数患者注射後1年仍能维持有效效果。此次规格拓展前，产品已获批 45mg╱瓶、75mg╱瓶、150mg╱瓶三类规格，分别适配预防型管理、联合治疗及综合年轻化等不同需 求；新增获批的60mg╱瓶、80mg╱瓶、100mg╱瓶、110mg╱瓶、120mg╱瓶、130mg╱瓶六类规格， 将进一步丰富产品选择谱系。 格隆汇1月16日丨四环医药(00460.HK)宣布，集团旗下渼颜空间生物科技(吉林)有限公司("渼颜空间")自 主研发的聚乳酸面部填充剂(市场简称「童颜针」)6个新增规格正式获国家药监局批准，这是继该产品 首次获批后的又一重要进展，进一步完善了公司在再生医美产品领域的市场布局。 ...

四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 關於渼顏空間 渼 顏 空 間 是 四 環 醫 藥 精 心 孵 化「一 站 式」新 型 醫 美 平 台，通 過 全 球 化 佈 局、全 面 專 業 的 醫 美 產 品 矩 陣、產 品 研 發、註 冊、生 產 及 銷 售 一 體 化 架 構，致 力 於 以 製 藥 企 業 的 嚴 謹 創 新 打 造 匠 心 鑄 造 中 國 醫 美 全 產 品 矩 陣 龍 頭 企 業。渼 顏 空 間 持 續 的 完 整 產 品 矩 陣，管 線 內 共 包 含60餘 款 產 品，覆 蓋 了 包 括 填 充、塑 形、支 撐、 光 電 設 備 及 皮 膚 管 理 類 等 輕 醫 美 的 基 礎 類 別。同 時，渼 ...

Group 1 - The core point of the article highlights that ST Huilun (300460) has faced regulatory penalties due to violations in information disclosure, specifically related to financial report inaccuracies from 2020 to 2022 [1][2] - On January 13, 2026, ST Huilun's stock closed at 8.91 yuan, down 1.22%, with a turnover rate of 7.32% and a trading volume of 205,600 shares, amounting to a transaction value of 184 million yuan [1] - The company received a total fine of 3 million yuan from the China Securities Regulatory Commission (CSRC) for failing to disclose significant financial information and for fabricating revenue and costs in its financial reports [1][2] Group 2 - On January 13, 2026, the net outflow of main funds was 17.58 million yuan, while retail and speculative funds showed a net inflow [2] - The company has stated that it has returned the occupied funds and that its production and operations are normal, indicating that the penalties do not lead to a situation of mandatory delisting due to major violations [1]

Core Viewpoint - ST Huilun has been penalized by the Guangdong Securities Regulatory Bureau for significant violations, including failure to disclose fund occupation and falsifying financial reports, resulting in a total fine of 11.4 million yuan [1][4]. Group 1: Violations - The company failed to disclose fund occupation matters in its 2020 annual report, with a total fund occupation amounting to 28.33 million yuan, which constituted 5.12% of the net assets disclosed in the report [2]. - ST Huilun inflated its revenue and costs in the 2021 and 2022 annual reports, with inflated revenues of 25.49 million yuan and 62.33 million yuan, representing 3.89% and 15.79% of the reported revenues for those years, respectively [3]. Group 2: Penalties - The Guangdong Securities Regulatory Bureau imposed a fine of 3 million yuan on ST Huilun and ordered corrective actions [4]. - The actual controller, Zhao Jiqing, was fined 4 million yuan for his direct involvement in the violations, while other executives received fines ranging from 60,000 to 1.5 million yuan [5][6]. Group 3: Company Background - ST Huilun is a national high-tech enterprise specializing in the research, production, and sales of new surface-mounted quartz crystal resonators, oscillators, and thermistors, listed on the Growth Enterprise Market since May 2015 [7]. - As of January 12, the company's stock price was 9.02 yuan per share, with a total market capitalization of 2.533 billion yuan [7].

Core Viewpoint - ST Huilun (300460) has faced regulatory penalties for information disclosure violations, impacting its financial reporting and leading to a total fine of 7 million yuan for the company and its actual controller [1][2]. Trading Information Summary - On January 12, ST Huilun closed at 9.02 yuan, up 10.27%, with a turnover rate of 11.33%, a trading volume of 318,100 shares, and a transaction value of 282 million yuan [1]. - The net inflow of main funds was 18.62 million yuan, indicating increased short-term interest from major investors [2]. Company Announcement Summary - The company and its actual controller, Zhao Jiqing, received an administrative penalty from the China Securities Regulatory Commission (CSRC) for failing to disclose fund occupation issues in 2020 and for inflating revenue and costs through fictitious transactions in 2021 and 2022 [1]. - The penalties included a fine of 3 million yuan for the company and 4 million yuan for Zhao Jiqing, with other responsible parties also receiving warnings and fines [1]. - The company has stated that it has returned the occupied funds and that its production and operations are normal, asserting that the penalties do not trigger major violations that would lead to forced delisting [1].

Core Viewpoint - ST Huilun has been penalized a total of 11.4 million yuan due to significant omissions and false records in its financial reports, as determined by the Guangdong Securities Regulatory Bureau [2][6]. Group 1: Violations - The company failed to disclose fund occupation matters in its 2020 annual report, with a total fund occupation amounting to 28.33 million yuan, which constituted 5.12% of the net assets disclosed in the report [5]. - In the 2021 and 2022 annual reports, ST Huilun inflated revenue by 25.49 million yuan and 62.33 million yuan respectively, representing 3.89% and 15.79% of the reported revenue for those years [5]. - The company also inflated total profits by 8.45 million yuan in 2021 and reduced profits by 1.41 million yuan in 2022, accounting for 6.13% and 0.91% of the reported total profits [5]. Group 2: Penalties - The Guangdong Securities Regulatory Bureau has ordered ST Huilun to rectify its practices, issued a warning, and imposed a fine of 3 million yuan on the company [6]. - The actual controller, Zhao Jiqing, was fined 4 million yuan and warned for his direct involvement in the violations [8]. - Other executives, including Han Qiaoyun and Deng Youqiang, received fines of 1.5 million yuan each, while other responsible personnel were fined between 60,000 and 800,000 yuan [9]. Group 3: Company Response - ST Huilun has expressed sincere apologies to investors and committed to improving internal governance, enhancing the quality of information disclosure, and complying with relevant laws and regulations [9]. - As of January 12, the company's stock price was 9.02 yuan per share, with a total market capitalization of 2.533 billion yuan [10].

Core Viewpoint - The approval of the injectable type A botulinum toxin product from Huons BioPharma marks a significant milestone for the company, enhancing its strategic positioning in the competitive Chinese medical aesthetics market, which is characterized by a growing number of similar products [2][3]. Group 1: Company Developments - The company has been seeking new growth avenues beyond its core hyaluronic acid business, with the injectable botulinum toxin being one of its earliest product initiatives [2]. - The company signed an exclusive agency agreement with Huons Global in September 2018, which was later deepened by acquiring a 25.4% stake in Huons BP in June 2021 [3]. - The recent approval is expected to enrich the company's product matrix and allow for comprehensive solutions for clients, aligning with market expectations for product pricing and positioning [3][6]. Group 2: Market Context - The Chinese medical aesthetics market has seen significant changes over the past seven years, with the number of approved botulinum toxin products increasing to seven, including the newly approved product from Huons BP [7]. - The market was previously dominated by two brands, Botox and Hengli, which held a combined market share of 100% until recent years [7]. - The current market dynamics indicate that while new entrants may face challenges due to intense competition and price pressures, there is still potential for growth, particularly in the mid-to-high-end market segment [9]. Group 3: Stock Market Reaction - Following the announcement of the product approval, the company's stock price rose by 2.69%, reflecting positive market sentiment [5].